Pharmacokinetic Study in Healthy Volunteers

Parkinson's Disease Clinical Trial

— NOCOFPK2  

Official title:

Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02554734
• Other study ID #: 3112003
• Status: Completed
• Phase: Phase 1
• First received: June 10, 2015
• Last updated: January 13, 2016
• Start date: August 2015
• Est. completion date: November 2015

Study information

• Verified date: January 2016
• Source: Orion Corporation, Orion Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Finnish Medicines Agency
• Study type: Interventional

Clinical Trial Summary

Phase I open, randomized cross-over pharmacokinetic study.

Description:

The purpose of this study is to investigate the pharmacokinetics of levodopa, carbidopa, 3-OMD and ODM-104 after repeated doses of levodopa, carbidopa and ODM-104: an open, randomized, multicenter study with crossover design in healthy males and females.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: November 2015
• Est. primary completion date: November 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Written informed consent (IC) obtained

• Good general health ascertained by detailed medical history and physical examinations

• Finnish speaking males and females 18-65 years of age

• Normal weight defined as body mass index (BMI) 19-30 kg/m2 (BMI=weight/height m2)

• Weight at least 55 kg

• Regular intestinal transit (no recent history of recurrent constipation, diarrhea, or other intestinal problems, and no history of major gastrointestinal surgery)

• Sexually active study subjects, unless surgically sterile must adhere to a proper form of contraception (hormonal contraception or intrauterine device on female partner, and an additional barrier method used at least by one of the partners) from the first study treatment administration until 3 months after the end-of-study visit

Exclusion Criteria:

• Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease or cancer (except local non-melanoma skin cancer) within the previous 2 years.

• Family history (parents, siblings) of clinically significant cardiac conduction disease.

• Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. As an exception, paracetamol for occasional pain is allowed. Hormonal contraception and hormone replacement therapy are allowed.

• Intake of any medication that could affect the outcome of the study.

• Any clinically significant abnormal laboratory value or physical finding (including ECG and vital signs) that in the opinion of the investigator could interfere with the interpretation of study results or cause a health risk for the subject if he/she takes part in the study.

• Known hypersensitivity to the active substances or the excipients of the drugs.

• Pregnant or lactating females.

• History of vasovagal collapses or vagal reactions with unexplained reason within the previous 2 years or a tendency for vasovagal reactions during blood sampling.

• HR < 40 bpm or > 90 bpm in the supine position after 10 min rest at the screening visit.

• At the screening visit:

systolic BP < 90 mmHg or > 150 mmHg in the supine position after 10 min rest diastolic BP < 50 mmHg or > 90 mmHg in the supine position after 10 min rest

• History of anaphylactic/anaphylactoid reactions.

• Strong tendency to motion sickness.

• Recent or current (suspected) drug abuse.

• Recent or current alcohol abuse; regular drinking of more than 21 units per week (males) or 16 units per week (females) (1 unit = 4 cl spirits or equivalent).

• Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day and/or inability to refrain from the use of nicotine containing products during the study (from the screening visit to the end-of-study visit).

Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability to refrain from using caffeine containing beverages 24 h before the first levodopa administration on the PK day (day 7) until collection of the 24 h PK sample in the morning of day 8.

• Blood donation or loss of a significant amount of blood within 90 days before the first study treatment administration.

• Participation in an investigational drug study or administration of an investigational drug within 90 days before the first study treatment administration.

• Veins unsuitable for repeated venipuncture or cannulation.

• Predictable poor compliance or inability to communicate well with the study centre personnel.

• Inability to participate in all treatment periods.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• levodopa, carbidopa, ODM-104

• levodopa, carbidopa, entacapone

Locations

Country	Name	City	State
Finland	Clinical Research Services Turku CRST	Turku

Sponsors (1)

Lead Sponsor	Collaborator
Orion Corporation, Orion Pharma

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Levodopa Peak Plasma Concentration (Cmax) and fluctuation of levodopa Cmax/Cmin, tau	Explore the Cmax of levodopa and fluctuation of levodopa Cmax/Cmin, tau	Blood samples collected frequently on day 7 for 24 hours.	No
Secondary	Carbidopa Peak Plasma Concentration (Cmax)	Explore Cmax of carbidopa	Blood samples collected frequently on day 7 for 24 hours.	No
Secondary	3-OMD Peak Plasma Concentration (Cmax)	Explore Cmax of 3-OMD	Blood samples collected frequently on day 7 for 24 hours.	No
Secondary	Levodopa Cmax, tau	Explore Cmax, tau of levodopa	Blood samples collected frequently on day 7 for 24 hours.	No
Secondary	Levodopa Cmin, tau	Explore Cmin, tau of levodopa	Blood samples collected frequently on day 7 for 24 hours.	No
Secondary	Levodopa Area under the plasma concentration versus time curve (AUC)	Explore AUC of levodopa	Blood samples collected frequently on day 7 for 24 hours.	No
Secondary	Carbidopa Area under the plasma concentration versus time curve (AUC)	Explore AUC of carbidopa	Blood samples collected frequently on day 7 for 24 hours.	No
Secondary	3-OMD Area under the plasma concentration versus time curve (AUC)	Explore AUC of 3-OMD	Blood samples collected frequently on day 7 for 24 hours.	No
Secondary	Levodopa Peak-trough fluctuation (PTF)	Explore PTF of levodopa	Blood samples collected frequently on day 7 for 24 hours.	No